* ImmuLogic Pharmaceutical Corp., of Waltham, Mass., received a$5 million license payment from Marion Merrell Dow Inc. as part ofa 1992 agreement between the two firms to jointly develop andcommercialize ImmuLogic's allergy therapeutics. The $5 millionbrings the total in license and milestone payments received byImmuLogic to $24 million. Under the 1992 pact, payments couldeventually total up to $42 million.

* U.S. Bioscience Inc., of West Conshohocken, Pa., was granted aproduct license in France to market Ethyol, a selective cytoprotectiveagent. France is the fifth European country to grant approval.

* Diatech Inc., of Londonderry, N.H., received a grant from the U.S.Energy Department to support trials of Tin-117m-DTPA, aradiopharmaceutical therapeutic for the palliation of painful bonemetastases in cancer patients.

* Boston Scientific Corp., of Natick, Mass., renewed its researchagreement with St. Elizabeth's Hospital, of Brighton, Mass., in thefield of cardiovascular gene therapy.

(c) 1997 American Health Consultants. All rights reserved.

No Comments